← All trials
NCT05940506
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2020
- Primary completion
- Jul 8, 2021
- Completion date
- Aug 18, 2021
- First posted
- Jul 11, 2023
- Last posted
- Jul 19, 2023
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Kintor Pharmaceutical Inc,Lead sponsor
- Fudan UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.